ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TNDM vs BVS // EV/EBITDA & P/E VALUATION

Tandem Diabetes Care Inc. (NASDAQ) VS. Bioventus Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: TNDM 3 — BVS 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNDM VS. BVS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TNDM BVS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 53.80% 68.30% -14.50 BVS /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 10.40% -45.40 BVS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 26.3x — TIE /valuation <GO>
Free Cash Flow Yield -2.15% 5.77% -7.92 BVS /fcf-yield <GO>
Operating Margin -18.50% 9.50% -28.00 BVS /operating-margins <GO>
Net Profit Margin -20.20% 4.00% -24.20 BVS /net-margins <GO>
Revenue Growth (YoY) 7.90% -0.90% +8.80 TNDM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 2.25 -2.05 BVS /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 BVS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 62.4 43.9 +18.42 TNDM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 51.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.38B $1.25B $126.5M TNDM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TNDM REV BVS REV TNDM GROSS % BVS GROSS % TNDM FCF BVS FCF
FY 2025 $1.01B $568.1M 53.8% 68.3% -$29.7M $72.1M
FY 2024 $940.2M $573.3M 52.1% 67.7% $5.0M $37.8M
FY 2023 $747.7M $512.3M — — -$31.8M $15.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNDM // BETA —
BVS // BETA —